Biontech announces fourth quarter and full year 2024 financial results and corporate update

Advanced oncology pipeline including more than 20 active phase 2 and phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate bnt327 and mrna cancer immunotherapies multiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of biontech's pipeline strategy and advancing the company towards becoming a diversified multi-product oncology portfolio company by 2030 completed acquisition of biotheus securing full control of next-generation immunomodulator candidate bnt327, a bispecific antibody targeting pd-l1 and vegf-a1 successfully launched jn.1- and kp.2-adapted covid-19 vaccines across different countries and regions and maintained global market leadership fourth quarter and full year 2024 revenues of €1.2 billion and €2.8 billion**, respectively full year 2024 net loss of €0.7 billion and diluted loss per share of €2.77 ($3.00)1 cash and cash equivalents plus security investments of €17.4 billion as of december 31, 2024 2 expects 2025 total reven ues between €1.7 billion and €2.2 billion conference call and webcast scheduled for march 10, 2025, at 8:00 a.m. edt (1:00 p.m.
BNTX Ratings Summary
BNTX Quant Ranking